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Synopsis: The functional roles of cancer-associated fibroblast markers in pancreatic ductal 
adenocarcinoma remain unclear. We showed that these fibroblasts possess molecular and functional 
heterogeneity and their expression of vimentin without α-smooth muscle actin is associated with 





Background: The tumor microenvironment, including cancer-associated fibroblasts (CAFs), plays 
various clinical roles in cancer growth. CAFs are a heterogeneous population and express a variety of 
mesenchymal markers. However, the clinical roles for CAFs expressing different markers in 
pancreatic ductal adenocarcinoma (PDAC) remain unknown. 
Methods: We reviewed 67 resected PDAC patients who had not received preoperative therapy. Each 
primary tumor was analyzed for vimentin and α-smooth muscle actin (α-SMA) expression by 
immunohistochemical and dual immunofluorescence staining.  
Results: There was no correlation between the percentage of cells expressing vimentin and α-SMA in 
the tumor stroma (Pearson’s correlation coefficient: r = 0.171). Higher vimentin expression (p = 
0.018) was associated with significantly shorter overall survival in PDAC patients. Using dual 
immunofluorescence staining, vimentin-positive CAFs were divided into two subpopulations: 
co-expression of α-SMA, and no co-expression of α-SMA. In PDAC, the level of co-expression had 
no effect on survival using univariate analysis (median survival time, 33.3 months for low 
co-expression vs. 18.2 months for high co-expression; log-rank, p = 0.143). However, multivariate 
analysis clarified that CAFs expressing vimentin alone was an independent predictor of poor survival 
(p = 0.014; hazard ratio, 2.305; 95% confidence interval, 1.181–4.497). 
Conclusions: Vimentin-positive CAFs without co-expression of α-SMA were associated with poor 







Cancer cells cannot survive without the coexistence of various types of stromal cells.1 The tumor 
microenvironment is formed by cancer cells and stromal cells, which interact by direct contact or 
paracrine mechanisms via various cytokines and chemokines.2 
Pancreatic ductal adenocarcinoma (PDAC), which has a poor prognosis and is one of the most 
lethal tumors3, generally possesses an intense stromal histopathology surrounding the cancer cells, 
which is called the desmoplastic stroma.4 The desmoplastic stroma occupies up to 80% of the entire 
cancer nodule in PDAC4 and fibroblasts are its major cellular component.5  
Collectively, the term “cancer-associated fibroblasts” (CAFs) is used to describe all fibroblasts 
within a tumor that show certain morphological and functional features.6 CAFs represent a 
heterogeneous population.7,8 They express various mesenchymal markers, such as vimentin and 
α-smooth muscle actin (α-SMA)9, and they consist of multiple cell types, including resident 
fibroblasts, tumor cells that have undergone epithelial to mesenchymal transition, adipocytes, bone 
marrow-derived mesenchymal cells, and pancreatic stellate cells.10, 11 Therefore, a specific marker 
has not yet been identified for CAFs. It is well known that CAFs play important roles in many steps 
during tumor development and progression in various tumors and metastatic lymph nodes.12, 13 
However, the functional differences in each CAF subpopulation in PDAC, as assessed by marker 
expression, remain unclear. 
In the tumor, fibroblasts can exert physiological functions, altering the status of the cancer cells 
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through paracrine effects and direct contact.14 We hypothesized that subpopulations of CAFs, with 
their distinct marker expression representing CAF heterogeneity, harbor different roles in PDAC 
progression. The present study aimed to answer two questions by determining the degree of 
expression of vimentin and α-SMA in the tumor stroma of clinical samples: 1) how heterogeneous is 
the expression of vimentin and α-SMA, which are expressed in CAFs, in the tumor stroma of 




Between January 2009 and December 2016, we retrospectively searched the electronic medical 
records of Shiga University of Medical Science Hospital to identify patients who underwent 
pancreatectomy for PDAC. Patients receiving preoperative chemotherapy or radiotherapy were 
excluded from the study. Sixty-seven patients were enrolled in the study. Postoperative adjuvant 
chemotherapy was performed in 67% (45/67) of the patients. Clinical and pathological reports were 
reviewed for age, sex, tumor size, histological differentiation, invasion depth (pT), nodal status (pN), 
and distant metastasis (pM). The follow-up period was a minimum of 2 years or until death. The 
median follow-up period was 25.8 months (range 1.6–103.9 months) and 28 patients (41.8%) died 
during this period. The pTNM classification was applied according to the 7th TNM classification of 
the Union for International Cancer Control.15 
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The protocol of this study was approved by the ethics committee of Shiga University of Medical 
Science (registration No. 29-171). We provided the patients the opportunity to opt out; however, the 
need for obtaining informed consent was waived because of the study’s retrospective design. 
 
Pathological specimens 
Surgical tissue blocks of the 67 PDAC patients were obtained. The specimens had previously been 
fixed in 10% formalin and embedded in paraffin. The tissue blocks were sliced into 4-µm-thick 
sections and mounted on glass slides. Several 4-µm-thick sections were cut from each paraffin block; 
one was stained with hematoxylin and eosin and examined by an experienced pathologist (K.M.) to 
verify the histopathological diagnosis. The others were subjected to immunohistochemical (IHC) 
staining and dual immunofluorescence (IF) staining for vimentin and α-SMA.  
 
IHC staining procedure 
For IHC staining, the slides were deparaffinized by xylene treatment, rehydrated in a graded 
ethanol series, and then heated in an electric kettle at 98℃ with antigen retrieval solution 
(Immunosaver®, Nisshin EM, Tokyo, Japan) for 45 min. Endogenous peroxidases were blocked by 
immersing sections in 3% H2O2 in 100% methanol for 10 min at 25℃, and the sections were 
subsequently incubated with a blocking reagent (Blocking One®, Nacalai Tesque, Kyoto, Japan) at 
25℃ for 20 min. The tissue sections were incubated overnight at 4℃ with an anti-vimentin antibody 
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(1:100, #5741S, Cell Signaling Technology, Inc., Danvers, MA, USA) or anti-α-SMA antibody 
(Clone 1A4, Dako, CA, USA). The following day, the slides were incubated with a secondary 
antibody (Simple Stain MAX PO®, NICHIREI BIOSCIENCES INC., Tokyo, Japan) for 30 min at 
25℃, and the antigen was visualized by 3,3′-diaminobenzidine staining (DAB®, Dako, California, 
USA) for 15 min. 
 
Dual IF staining procedure 
Four-micrometer-thick sections were processed using the IHC protocol as above. Vimentin was 
detected with an anti-vimentin antibody (1:100, #5741S, Cell Signaling Technology, Inc.), and 
α-SMA was detected with an anti-αSMA antibody (1:100, #ab7817, Abcam plc, Cambridge, UK). 
The secondary antibodies employed were Alexa Fluor® 488 goat anti-mouse (A-11029) and Alexa 
Fluor® 594 goat anti-rabbit (A-11012) (Molecular Probes, Invitrogen, Carlsbad, CA, USA) 
antibodies at dilutions of 1:200. The tissues were incubated with secondary antibodies for 60 min. 
ProLong® Diamond Antifade Mountant with 4′,6-diamidino-2-phenylindole (DAPI) (P36962, 
Molecular probes, Invitrogen/Thermo Fisher Scientific, Waltham, MA, USA) was used as the 
mounting agent. A BZ-X800 microscope (Keyence, Osaka, Japan) was used for image analysis. 
 
Evaluation of immunostaining 
Blinded microscopic evaluation of the slides was performed by an experienced pathologist (K.M.). 
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The pathologist, in consultation with the first author (H.M.), demarcated three areas in the central 
part of the tumor at a magnification of 200× for analyses. We selected the stromal area that did not 
contain cancer cells, but which had ductal structures, and also stained positive for hematoxylin and 
eosin. The percentage of stained stromal cells was assessed using Image J (National Institutes of 
Health, Bethesda, MD, USA) for the IHC staining. Furthermore, the images were captured in three 
different stromal areas which were randomly selected in the central part of the tumor at 200× 
magnification for the IF staining on microscope with BZ-X800 (Keyence, Osaka, Japan), and the 
quantification was performed using Hybrid Cell Count BZ-H4C analyzer software (Keyence, Osaka, 
Japan). The percentage of stained stromal cells area and the stromal cell number was calculated. 
Then, the average percentage of stained stromal cells and the average stromal cell number per tumor 
area (mm2) was calculated. The average stromal cell number in the tumor was calculated as [the 
average stromal cell number per tumor area (count/mm2)] × [maximum tumor area (mm2)]. 
 
Statistical analysis 
To determine a suitable cut-off value for the expression of each marker, we used a receiver 
operating characteristic (ROC) curve analysis based on patient death at the median follow-up time, 
according to a previous report.16 A suitable cut-off value for the intensity of staining was defined as 
the point on the ROC curve closest to the (0,1) point (Supplementary figure 1). Then, this cut-off was 
used for the analysis of overall survival (OS) and recurrent free survival (RFS).  
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Categorical variables are expressed as numbers and percentages, whereas continuous variables are 
expressed as medians with interquartile ranges. Fisher’s exact tests (for categorical variables) and 
Mann-Whitney U tests (for continuous variables) were used to compare factors. OS was calculated 
from the date of surgery to the date of the last follow-up or patient death. RFS was the time from 
curative surgery to the time of first tumor recurrence or the final follow-up date. Univariate survival 
analysis was performed according to the Kaplan-Meier method, and survival was compared using the 
log-rank test. Multivariate analysis was performed using the Cox proportional hazards regression 
model. The level for significance was p < 0.05 and confidence intervals (CIs) were determined at the 
95% level. All statistical analyses were performed using EZR (Saitama Medical Center, Jichi 
Medical University, Saitama, Japan), which is a graphical user interface for R (version 2.13.0; The 
Foundation for Statistical Computing, Vienna, Austria).17 
 
Results 
Differential expression of CAF mesenchymal markers in PDAC patients 
Figure 1a shows hematoxylin and eosin staining of a representative tumor and Figure 1b shows 
vimentin and α-SMA expression in the tumor stroma by IHC staining. The median vimentin 
expression in the tumor stroma was 16.4% (ranging from 5% to 28%), and the median α-SMA 
expression was 15.2% (ranging from 4% to 29%) (Figure 1c, 1d). There was no correlation between 
vimentin and α-SMA expression in the tumor stroma (Pearson’s correlation coefficient: r = 0.171; 
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Figure 1e).  
We performed dual IF staining for vimentin and α-SMA to confirm their co-expression or separate 
expression in individual fibroblasts. Figure 1f shows the co-expression of vimentin and α-SMA in 
individual cells, and 5.9% of cells (median, ranging from 1.3% to 11.8%) expressed both markers in 
the tumor stroma (Figure 1h). Figure 1g shows the fibroblasts expressing either vimentin (singleVim) 
or α-SMA (singleSMA). The median expression of singleVim and singleSMA was 9.3% (ranging 
from 1.9% to 23.0%) and 8.4% (ranging from 2.2% to 22.8%) of cells in the tumor stroma, 
respectively (Figure 1i, 1j). Considering only fibroblasts, 24.5% (median, ranging from 6.7% to 
44.8%) co-expressed vimentin and α-SMA. In addition, the median CAF number in the tumor was 
2,805,673 cells (ranging from 135,356 to 15,691,980 cells), and the median CAF number per tumor 
area was 4140 cells/mm2 (ranging from 1,725 to 6,796 cells/mm2). 
 
Vimentin expression in the PDAC stroma is associated with poor survival 
The patients were classified according to the cut-off value of vimentin expression determined by 
ROC curve analysis. Forty-three (64.2%) and 24 (35.8%) patients were categorized in the low 
vimentin expression (Vimlow) and high vimentin expression (Vimhigh) groups, respectively. Table 1 
shows the characteristics and clinicopathological features of each group. There were no significant 
differences in tumor markers (Carcinoembryonic antigen, Carbohydrate antigen 19-9 (CA19-9), and 
Dupan-2), tumor size, TNM classification, and histological differentiation. With respect to RFS, 
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there was no significant difference between the Vimhigh and Vimlow groups (median RFS time, 9.9 
months vs. 13.9 months; log-rank, p = 0.072) (Figure 2a). In contrast, the OS of the Vimhigh group 
was significantly shorter than that of the Vimlow group (median survival time (MST), 15.0 months vs. 
33.3 months; log-rank, p = 0.018) (Figure 2b). 
In contrast, there was no significant difference between the high and low α-SMA expression 
groups with respect to RFS (median RFS time, 17.5 months vs. 10.2 months; log-rank, p = 0.138) 
(Figure 2c). However, the OS of the high α-SMA expression group was significantly longer than that 
of the low α-SMA expression group (MST, 33.0 months vs. 19.0 months; log-rank, p = 0.048) 
(Figure 2d). 
Furthermore, as to CAF number in the tumor, a high number group was associated with 
significantly shorter overall survival (OS) than a low number group (MST, 15.0 months vs. 35.8 
months; log-rank, p = 0.002), and was associated with a shorter recurrent-free survival (RFS) 
(median RFS time, 10.1 months vs. 18.0 months; log-rank, p = 0.077). However, in regard to CAF 
number per tumor area, there was no significant difference between high and low number groups in 
OS (MST, 19.0 months vs. 29.9 months; log-rank, p = 0.332) and RFS (median RFS time, 10.2 
months vs. 12.0 months; log-rank, p = 0.312) (Supplementary figure 2). 
 
The subpopulation of CAFs co-expressing vimentin and α-SMA does not affect PDAC survival 
Regarding CAFs with co-expression, 38 patients (56.7%) were categorized in the low 
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co-expression group, and 29 patients (43.3%) were assigned to the high co-expression group. There 
were no significant differences in patient characteristics between the two groups (Table 2). As shown 
in Figure 3a and 3b, there was no significant difference between the low and high co-expression 
group in RFS (median RFS time, 12.5 months vs. 11.1 months; log-rank, p = 0.511) and OS (MST, 
33.3 months vs. 18.2 months; log-rank, p = 0.143). 
As for single α-SMA expression, 33 patients (49.3%) were assigned to the low singleSMA 
expression (singleSMAlow) group, and 34 patients (50.7%) to the high singleSMA expression 
(singleSMAhigh) group. Body mass index was significantly lower in the singleSMA low group 
(20.7kg/m2 vs. 22.4kg/m2, p = 0.045), and platelet count was significantly lower (17.7/µl vs. 20.7/µl, 
p = 0.019) in the singleSMAlow group. There were no significant differences in tumor markers (CEA, 
CA19-9, and Dupan-2), tumor size, TNM classification, and histological differentiation. With regard 
to recurrent-free survival, there was no significant difference between the two groups (log-rank p = 
0.222). However, the singleSMAlow group had a shorter overall survival compared to the 
singleSMAhigh group (log-rank p = 0.065) (Supplementary figure 3). 
 
Expression of vimentin without α-SMA in CAFs indicates poor survival in PDAC 
Next, we analyzed another subpopulation, namely CAFs with singleVim expression. The patients 
were classified according to the cut-off value of singleVim expression determined by ROC curve 
analysis. Forty-five patients (67.2%) were categorized in the low singleVim expression 
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(singleVimlow) group and 22 patients (32.8%) were categorized in the high singleVim expression 
(singleVimhigh) group. The clinicopathological characteristics of each group are shown in Table 2. 
CA19-9 (p = 0.049) and Dupan-2 (p = 0.039) levels were significantly higher in the singleVimhigh 
group, and tumor size was significantly larger in the singleVimhigh group (p = 0.017). There were no 
significant differences in TNM classification and histological differentiation, but more lymphatic 
invasion presented in the singleVimlow group (p = 0.037). As shown in Figure 3c and 3d, the 
singleVimhigh group had a significantly shorter OS (MST, 15.0 months vs. 33.0 months; log-rank, p = 
0.014) and RFS (median RFS time, 9.2 months vs. 15.1 months; log-rank, p = 0.035) than the 
singleVimlow group did. 
Table 3 shows univariate and multivariate analyses of clinicopathological factors and CAF 
markers determined by dual IF staining. In the univariate analysis, the singleVimhigh group (log-rank, 
p = 0.014) was significantly associated with poor survival. Multivariate analysis clarified that the 




In the present study, we clarified two important clinical findings. First, CAFs constituted a 
heterogeneous population in human PDAC. There was no correlation between vimentin and α-SMA 
expression in CAFs, and CAFs not only expressed vimentin and α-SMA separately, but also 
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co-expressed them. Second, the frequency of CAFs only expressing vimentin was associated with 
poor survival in PDAC. PDAC is aggressive and lethal, and morbidity due to this disease is 
increasing worldwide.3 Surgery is the only curative therapy currently available. However, pancreatic 
resection is an aggressive therapy with a high complication rate.18-20 Recently, two novel, 
combination chemotherapies have led to a major improvement in the survival of patients with 
PDAC.21, 22 However, these cytotoxic therapies also have severe side effects, and the survival 
benefits afforded by them are not ideal. PDAC is characterized as a desmoplastic mass, and treatment 
strategies targeting the tumor stroma are considered to have great potential in PDAC. The present 
study suggests that CAFs expressing vimentin alone have a tumor-promoting role in human clinical 
samples. If CAFs can be classified by function, a specific CAF subpopulation associated with poor 
outcomes might become a new target candidate for PDAC treatments. 
First, our study showed that CAFs comprised a heterogeneous population in human PDAC, with 
cells not only co-expressing vimentin and α-SMA but also expressing vimentin and α-SMA 
separately. PDAC is accompanied by intense fibrosis of the tumor stroma, and CAFs are the major 
cellular components of this stroma.5 Previous reports have reviewed the multiple sources of CAFs, 
such as resident fibroblasts, tumor cells converted via epithelial to mesenchymal transition, 
adipocytes, bone marrow-derived mesenchymal cells, and pancreatic stellate cells10, 11, and their 
molecular heterogeneity.7, 8 However, to the best of our knowledge, there have been no reports 
investigating the degree of co-expression of each CAF marker in clinical samples. The present study 
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showed that approximately 25% of CAFs in the tumor stroma co-express vimentin and α-SMA. It is 
necessary to examine multiple CAF markers to investigate CAF subpopulations and their clinical 
roles, because each specific marker cannot identify a particular CAF subtype and solitary CAF 
markers do not reflect all CAFs.7, 8  
Second, we demonstrated that the frequency of CAFs expressing vimentin alone was associated 
with poor survival in PDAC. Previous reports had associated survival with only one specific marker, 
for example α-SMA23-26 or fibroblast activated protein.27, 28 Regarding α-SMA, some reports 
demonstrated that high α-SMA expression is a poor prognostic factor in PDAC, namely that CAFs 
with α-SMA expression are tumor-promoting.23, 24 In contrast, depletion of α-SMA expression was 
shown to accelerate PDAC progression with shortened survival, namely that CAFs with α-SMA 
expression are tumor-suppressive.25, 26 Thus, the clinical role of α-SMA-expressing CAFs is still 
controversial in PDAC. Regarding vimentin expression, to the best of our knowledge, there have 
been no reports investigating its clinical role in the tumor stroma of PDAC.  
Recently, defining the CAF subtype by the expression pattern of multiple markers was proposed.29 
However, we believe that we are the first to show the correlation between patient survival and 
expression of multiple CAF markers in the PDAC stroma. Because of the molecular heterogeneity of 
CAFs, single-stain IHC cannot evaluate the clinical impact of co-expression or single expression in 
individual fibroblasts. In the present study, stromal vimentin expression was associated with poor 
survival in PDAC using IHC single staining. Therefore, we divided the vimentin-expressing 
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population into two subpopulations determined by dual IF staining, one expressing both vimentin 
and α-SMA, and one expressing only vimentin. Our findings demonstrated that the subpopulation 
expressing only vimentin possessed a tumor-promoting role, while the subpopulation co-expressing 
vimentin and α-SMA was not related to PDAC survival. Recent report proposed classification of 
subtypes of fibroblast on the basis of function, such as tumor-restraining CAFs, tumor-promoting 
CAFs, secretory CAFs, and extracellular matrix-remodeling CAFs.9 Our results suggested that 
α-SMA positive CAFs have tumor-restraining role and vimentin positive CAFs have 
tumor-promoting role. Then, tumor-promoting role is canceled by tumor-restraining role in 
co-expressing CAFs. Thus, multiple staining is a critical method to clarify the CAF subpopulation. 
To the best of our knowledge, our study is the first to investigate the clinical role of CAF 
subpopulations by using human clinical samples of PDAC. However, it is difficult to determine how 
single vimentin expressing CAFs induce tumor-promoting environment in this study. Therefore, the 
function of single vimentin expressing CAFs should be investigated by the culture of CAF of human 
PDAC in the future. 
The present study had several limitations. First, this was a retrospective study. Second, the number 
of enrolled patients was small. Third, previously processed clinical samples were used; hence, 
inconsistencies in sample processing conditions were possible, including formalin fixation time and 
time after resection to analysis, which may have influenced the staining results. However, we believe 
that the premise of association of multiple CAF markers and clinical prognosis, which we 
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demonstrated in this study, will be helpful for future CAF research. 
In conclusion, we observed that CAFs possessed molecular and functional heterogeneity, and that 
the vimentin-positive CAFs without α-SMA co-expression were associated with poor survival in 
PDAC. If tumor-promoting CAFs can be identified selectively, these may be useful for the 
development of new therapeutic strategies for PDAC. Future novel studies are needed to clarify the 
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Figure 1. α-SMA-expressing and vimentin-expressing CAFs are a heterogeneous population. (a) 
Loupe image of H&E-stained tumor tissue. (b) H&E, vimentin, and α-SMA staining in the tumor 
stroma. Vimentin and α-SMA are expressed in mesenchymal cells and are stained brown (200× 
magnification). (c, d) Distribution of the percentage of vimentin-expressing (c) and 
α-SMA-expressing (d) cells in the central part of the tumor. (e) Scatter diagram comparing the 
relationship between vimentin and α-SMA expression rate. Pearson’s correlation coefficient (r) is 
0.171. (f, g) Immunofluorescence staining of vimentin and α-SMA in the tumor stroma (400× 
magnification). Vimentin and α-SMA co-expressed in the same fibroblast (f). Fibroblasts expressing 
only α-SMA (white circle) and only vimentin (white dotted circle) existed in the tumor stroma (g). (h, 
i, j) Distribution of the percentage of cells co-expressing α-SMA and vimentin (h), vimentin alone 
(singleVim) (i), and α-SMA alone (singleSMA) (j) in the central part of the tumor over the 67 cases. 
H&E, hematoxylin and eosin; α-SMA, alpha-smooth muscle actin; CAFs, cancer-associated 
fibroblasts. 
 
Figure 2. Survival outcome in PDAC with respect to single IHC staining of CAFs. (a, b) 
Kaplan-Meier analyses of RFS (a) and OS (b) according to vimentin expression in the central part of 
the tumor stroma. (c, d) Kaplan-Meier analyses of RFS (c) and OS (d) according to α-SMA 
expression in the central part of the tumor stroma.  
CAFs, cancer-associated fibroblasts; PDAC, pancreatic ductal adenocarcinoma; IHC, 
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immunohistochemical; RFS, recurrent free survival; OS, overall survival; α-SMA, alpha-smooth 
muscle actin. 
 
Figure 3. Prognostic impact in PDAC of the CAF subpopulation determined by dual IF staining. (a, 
b) Kaplan-Meier analyses of RFS (a) and OS (b) according to the co-expression of vimentin and 
α-SMA in the central part of the tumor stroma determined by dual IF staining. (c, d) Kaplan-Meier 
analyses of RFS (c) and OS (d) according to the degree of vimentin single expression in the central 
part of the tumor stroma determined by dual IF staining. 
CAFs, cancer-associated fibroblasts; IF, immunofluorescence; PDAC, pancreatic ductal 






Supplementary Figure legends 
Supplementary figure 1. Receiver operating characteristic (ROC) curve of Vimentin expression rate 
(a), co-expression rate of α-SMA and Vimentin (b), single α-SMA expression (c), and single 
Vimentin expression (d) for alive or dead analysis at the median follow-up time.  
The areas under the ROC are 0.604 (95% CI, 0.448–0.760), 0.538 (95% CI, 0.396–0.681), 0.655 
(95% CI, 0.524–0.786), and 0.598 (95% CI, 0.452–0.743), respectively. 
 
Supplementary figure 2. Kaplan-Meier analyses of RFS (a) and OS (b), according to the CAF 
number in the tumor, and of RFS (c) and OS (d), according to the CAF number per tumor area, as 
determined by dual IF staining. 
CAF, cancer-associated fibroblasts; RFS, recurrent-free survival; OS, overall survival; IF, 
immunofluorescence. 
 
Supplementary figure 3. Kaplan-Meier analyses of RFS (a) and OS (b) according to the degree of 
α-SMA single expression in the central part of the tumor stroma, as determined by dual IF staining. 





Table 1. Characteristics of the 67 patients with respect to vimentin expression 
   Vimentin expression 





    
Background     
 Age, years  71.0 (62.0-75.5) 71 (63.8-75.3) 0.927 
 Gender, male / female  28 (65%) / 15 (35%) 14 (58%) / 10 (42%) 0.608 
 Body mass index, kg/m2  22.2 (19.6-23.7) 20.5 (17.6-23.0) 0.166 
 Diabetes mellitus  11 (26%) 12 (50%) 0.061 
 Hypertension  15 (35%) 11 (46%) 0.438 
 Biliary drainage  13 (30%) 8 (33%) 0.791 
 Adjuvant chemotherapy  30 (70%) 15 (63%) 0.594 
Preoperative findings      
 Hemoglobin, g/dL  12.4 (11.2-13.8) 12.5 (11.5-13.7) 0.605 
 White blood cell count, /μL  5000 (4400-6000) 5700 (4575-7325) 0.102 
 Platelet count, /μL  19.4 (17.2-22.7) 18.2 (15.3-22.3) 0.403 
 Prothrombin activity, %  92.0 (86.5-100.0) 92.0 (78.8-101.0) 0.891 
 Albumin, g/dL  3.5 (3.4-3.9) 3.8 (3.5-3.9) 0.315 
 Aspartate aminotransferase, U/L  21 (18-41) 26 (20-46) 0.425 
 Alanine aminotransferase, U/L  23 (15-48) 30 (19-54) 0.605 
 Total bilirubin, g/dL  0.79 (0.56-1.27) 0.67 (0.50-1.06) 0.539 
 Creatinine, mg/dL  0.69 (0.59-0.96) 0.66 (0.58-0.75) 0.239 
 C-reactive protein, mg/dL  0.09 (0.05-0.31) 0.09 (0.06-0.19) 0.948 
 Hemoglobin A1c, %  6.0 (5.8-7.4) 7.7 (5.9-9.3) 0.088 
Tumor markers      
 Carcinoembryonic antigen, mg/dL  4.0 (2.4-6.2) 4.6 (3.8-6.6) 0.252 
 Carbohydrate antigen 19-9, mg/dL  98.0 (37.5-211.0) 202.0 (44.8-357.0) 0.182 
 Dupan-2, mg/dL  110.0 (25.0-450.0) 155.0 (57.8-732.5) 0.231 
Operative findings      
 Operation method    0.470 
   Pancreaticoduodenectomy  27 (63%) 13 (54%)  
   Distal pancreatectomy  12 (28%) 6 (25%)  
   Total pancreatectomy  4 (9%) 5 (21%)  
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 Operation time, min  488 (386-596) 508 (382-540) 0.761 
 Blood loss, mL  945 (603-1716) 928 (713-1566) 0.891 
Histopathological findings      
 Tumor size, mm  23.0 (20.5-29.5) 30.0 (24.0-36.3) 0.050 
 Histological differentiation    0.283 
   Well  13 (30%) 8 (33%)  
   Moderately   22 (51%) 15 (63%)  
   Poorly  8 (19%) 1 (4%)  
 pT classification    0.788 
   pT1  2 (5%) 1 (4%)  
   pT2  2 (5%) 0 (0%)  
   pT3  39 (90%) 23 (96%)  
   pT4  0 (0%) 0 (0%)  
 pN classification    0.799 
   pN0  18 (42%) 9 (38%)  
   pN1  25 (58%) 15 (62%)  
 pM classification    0.533 
   pM0  41 (95%) 24 (100%)  
   pM1  2 (5%) 0 (0%)   
 pStage (UICC 7th)    0.816 
   Stage IA  1 (%) 0 (0%)  
   Stage IB  2 (%) 0 (0%)  
   Stage IIA  14 (%) 9 (%)  
   Stage IIB  24 (%) 15 (%)  
   Stage III   0 (0%) 0 (0%)  
   Stage IV  2 (%) 0 (0%)  
 Lymphatic invasion    0.052 
   Negative  1 (2%) 4 (17%)  
   Positive  42 (98%) 20 (83%)  
 Venous invasion    1.000 
   Negative  2 (5%) 1 (4%)  
   Positive  41 (95%) 23 (96%)  
 Neural invasion    0.614 
29 
 
   Negative  2 (5%) 2 (8%)  
   Positive  41 (95%) 22 (92%)  
Data are expressed as medians with interquartile ranges or as numbers with percentages. 
pT, invasion depth; pN, nodal status; pM, distant metastasis; UICC 7th, 7th TNM classification of the





Table 2. Characteristics of the 67 patients with respect to co-expression of vimentin and α-SMA, and single expression of vimentin 














   (n=38) (n=29)  
Background        
 Age, years 70 (63-76) 71 (62-75) 0.990  71 (62-75) 71 (65-76) 0.878 
 Gender, male / female 24 / 14 (63% / 37%) 18 / 11 (62% / 38%) 1.000  29 / 16 (64% / 36%) 13 / 9 (59% / 41%) 0.789 
 Body mass index, kg/m2 22.2 (19.4-23.5) 20.9 (17.3-23.4) 0.519  21.8 (19.1-23.6) 21.0 (17.8-23.4) 0.435 
 Diabetes mellitus 12 (32%) 11 (38%) 0.613  14 (31%) 9 (41%) 0.584 
 Hypertension 13 (34%) 13 (45%) 0.452  16 (36%) 10 (45%) 0.594 
 Biliary drainage 10 (26%) 11 (38%) 0.426  13 (29%) 8 (36%) 0.582 
 Adjuvant chemotherapy 26 (68%) 19 (66%) 1.000  32 (71%) 13 (59%) 0.409 
Preoperative findings         
 Hemoglobin, g/dL 12.5 (11.2-13.7) 12.3 (11.3-14.0) 0.635  12.6 (11.3-13.8) 12.0 (11.2-13.2) 0.310 
 White blood cell count, /μL 5100 (4600-6100) 5000 (4300-6700) 0.608  5000 (4400-6100) 5450 (4525-7375) 0.262 
 Platelet count, /μL 18.8 (16.8-22.4) 19.7 (15.5-23.6) 0.995  19.4 (17.3-22.4) 18.2 (15.0-23.2) 0.431 
 Prothrombin activity, % 89.5 (83.3-98.0) 93.0 (87.0-103.0) 0.142  92.0 (87.0-101.0) 91.5 (78.3-100.8) 0.466 
 Albumin, g/dL 3.6 (3.4-4.0) 3.7 (3.4-3.9) 1.000  3.6 (3.4-3.9) 3.6 (3.4-3.9) 0.763 
 Aspartate aminotransferase, U/L 20.5 (17.3-42.0) 27.0 (19.0-45.0) 0.382  21.0 (16.0-37.0) 29.5 (20.5-47.3) 0.092 
 Alanine aminotransferase, U/L 23.0 (14.3-47.3) 34.0 (20.0-53.0) 0.285  22.0 (14.0-45.0) 32.5 (22.3-62.5) 0.118 
 Total bilirubin, g/dL 0.73 (0.52-1.38) 0.83 (0.58-1.10) 0.864  0.76 (0.53-1.11) 0.86 (0.59-1.25) 0.669 
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 Creatinine, mg/dL 0.70 (0.59-0.90) 0.64 (0.56-0.81) 0.362  0.66 (0.58-0.90) 0.69 (0.58-0.81) 0.616 
 C-reactive protein, mg/dL 0.09 (0.05-0.29) 0.09 (0.05-0.30) 0.914  0.09 (0.05-0.30) 0.09 (0.06-0.20) 0.910 
 Hemoglobin A1c, % 6.3 (5.8-7.6) 7.0 (5.8-8.7) 0.434  6.3 (5.8-7.7) 6.7 (5.8-8.9) 0.596 
Tumor markers         
 Carcinoembryonic antigen, mg/dL 4.2 (2.6-6.6) 3.9 (3.4-6.0) 0.995  4.0 (2.5-6.0) 4.1 (3.8-7.2) 0.094 
 Carbohydrate antigen 19-9, mg/dL 102 (37-262) 99 (39-346) 0.737  94 (37-176) 258 (67-379) 0.049 
 Dupan-2, mg/dL 65 (25-750) 135 (60-425) 0.311  69 (25-230) 360 (71-905) 0.039 
Operative findings         
 Operation method   0.733    0.321 
   Pancreaticoduodenectomy 23 (61%) 17 (59%)   28 (62%) 12 (54%)  
   Distal pancreatectomy 11 (29%) 7 (24%)   13 (29%) 5 (23%)  
   Total pancreatectomy 4 (10%) 5 (17%)   4 (9%) 5 (23%)  
 Operation time, min 491 (385-549) 500 (382-602) 0.826  484 (378-586) 516 (431-573) 0.556 
 Blood loss, mL 928 (383-1538) 948 (781-1805) 0.161  931 (736-1645) 994 (736-1595) 0.551 
Histopathological findings         
 Tumor size, mm 23.0 (19.0-31.0) 28.0 (24.0-36.0) 0.046  24.0 (21.0-28.0) 31.0 (23.0-40.0) 0.017 
 Histological differentiation   0.613    0.622 
   Well 10 (26%) 11 (38%)   15 (33%) 6 (27%)  
   Moderately  22 (58%) 15 (52%)   23 (51%) 14 (64%)  
   Poorly 6 (16%) 3 (10%)   7 (16%) 2 (9%)  
 pT classification   1.000    1.000 
   pT1 2 (5%) 1 (3%)   2 (4%) 1 (5%)  
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   pT2 2 (5%) 0 (0%)   2 (4%) 0 (0%)  
   pT3 34 (90%) 28 (97%)   41 (92%) 21 (95%)  
   pT4 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
 pN classification   0.804    0.428 
   pN0 16 (42%) 11 (38%)   20 (44%) 7 (32%)  
   pN1 22 (58%) 18 (62%)   25 (56%) 15 (68%)  
 pM classification   0.502    1.000 
   pM0 36 (95%) 29 (100%)   43 (96%) 22 (100%)  
   pM1 2 (5%) 0 (0%)    2 (4%) 0 (0%)   
 pStage (UICC 7th)   0.580    0.730 
   Stage IA 1 (3%) 0 (0%)   1 (2%) 0 (0%)  
   Stage IB 2 (5%) 0 (0%)   2 (4%) 0 (0%)  
   Stage IIA 12 (32%) 11 (38%)   16 (36%) 7 (32%)  
   Stage IIB 21 (55%) 18 (62%)   24 (54%) 15 (68%)  
   Stage III 0 (0%) 0 (0%)   0 (0%) 0 (0%)  
   Stage IV 2 (5%) 0 (0%)   2 (4%) 0 (0%)  
 Lymphatic invasion   0.645    0.037 
   Negative 2 (5%) 3 (10%)   1 (2%) 4 (18%)  
   Positive 36 (95%) 26 (90%)   44 (98%) 18 (82%)  
 Venous invasion   1.000    1.000 
   Negative 2 (5%) 1 (3%)   2 (4%) 1 (5%)  
   Positive 36 (95%) 28 (97%)   43 (96%) 21 (95%)  
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 Neural invasion   0.628    0.593 
   Negative 3 (8%) 1 (3%)   2 (4%) 2 (9%)  
   Positive 35 (92%) 28 (97%)   43 (96%) 20 (91%)  
Data are expressed as medians with interquartile ranges or as numbers with percentages. 





Table 3. Univariate and multivariate analyses of conventional prognostic factors and expression of CAF 
markers determined by dual IF staining 



















Expression of CAF markers  
singleVimlow group 45 33.0 63.1 0.014  1 
singleVimhigh group 22 15.0 30.3  2.305 1.181-4.497 0.014 
Expression of CAF markers        
  Low co-expression group 38 33.3 58.4 0.143     
  High co-expression group 29 18.2 44.3      
Age  
  < 65 years old 21 35.5 72.4 0.019  1 
  ≥ 65 years old 46 19.6 42.2  1.803 0.870-3.738 0.113 
BMI  
  < 22 kg/m2 35 18.2 42 0.172  
  ≥ 22 kg/m2 32 33.3 63  
Adjuvant chemotherapy  
  Yes 45 26.0 56.1 0.129  
  No 22 13.7 42  
Tumor size  
  < 20 mm 13 NA 70 0.037  1   
  ≥ 20 mm 54 22.1 48.1  1.900 0.653-5.529 0.239 
pT classification  
  pT1 / pT2 5 48.2 100 0.117  
  pT3 / pT4 62 20.2 47.3  
pN classification  
  pN0 27 35.5 66.2 0.131  
  pN1 40 19.6 41.5  
pM classification  












   
  well 21 29.9 57.4 0.871  
  moderately 37 26.0 52.0  
  poorly 9 16.6 37.5  
lymphatic invasion  
  positive 62 25.9 53.1 0.834  
  negative 5 15.2 40.0  
venous invasion  
  positive 64 22.1 49.3 0.323  
  negative 3 29.9 100.0  
neural invasion  
  negative 4 NA 100.0 0.027  1   
  positive 63 22.1 48.3  7.58E+07 0.000-NA 0.996 
CAF, cancer-associated fibroblast; IF, immunofluorescence; MST, median survival time; NA, not available; Vim, 
vimentin; BMI, body mass index; pT, invasion depth; pN, nodal status; pM, distant metastasis 
 
